ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

EXEL Exelixis Inc

22,25
0,52 (2,39%)
21 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Exelixis Inc EXEL NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,52 2,39% 22,25 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
21,88 21,84 22,225 22,20 21,73
mais cotações »

Notícias Recentes

Data Hora Fonte Título
28/05/202417:05BWExelixis to Present at the William Blair 44th Annual Growth..
20/05/202409:00BWExelixis Announces Settlement of CABOMETYX® (cabozantinib)..
07/05/202417:05BWExelixis to Webcast Fireside Chats as Part of Investor..
30/04/202417:05BWExelixis Announces First Quarter 2024 Financial Results and..
16/04/202417:05BWExelixis to Release First Quarter 2024 Financial Results on..
27/02/202418:05BWExelixis to Webcast Fireside Chats as Part of Investor..
06/02/202418:05BWExelixis Announces Fourth Quarter and Fiscal Year 2023..
01/02/202418:05BWExelixis to Webcast Fireside Chats as Part of Investor..
25/01/202410:00BWExelixis Announces Detailed Results of Phase 3 CONTACT-02..
23/01/202418:05BWExelixis to Release Fourth Quarter and Fiscal Year 2023..
22/01/202419:00BWOpdivo® (nivolumab) in Combination with CABOMETYX®..
18/01/202418:05BWEuropean Patent Office Rules in Favor of Exelixis on..
07/01/202418:00BWExelixis Announces Preliminary Fiscal Year 2023 Financial..
02/01/202418:05BWExelixis to Present at the 42nd Annual J.P. Morgan..
07/12/202318:05BWExelixis 2023 R&D Day: Science & Strategy to be Webcast on..
04/12/202310:02BWExelixis Announces Initiation of the STELLAR-305 Phase 2/3..
04/12/202310:00BWExelixis and Arcus Biosciences Announce Clinical Trial..
21/11/202318:05BWExelixis to Present at the Piper Sandler 35th Annual..
10/11/202311:00BWExelixis Announces Encouraging Results from Expansion Cohort..
01/11/202317:05BWExelixis Announces Third Quarter 2023 Financial Results and..
22/10/202303:30BWDetailed Results from Phase 3 CABINET Pivotal Trial..
18/10/202317:05BWExelixis to Release Third Quarter 2023 Financial Results on..
12/09/202309:00BWExelixis and Insilico Medicine Enter into Exclusive Global..
31/08/202317:05BWExelixis to Webcast Fireside Chats as Part of Investor..
24/08/202309:00BWExelixis Announces Positive Results from Phase 3 CABINET..
23/08/202317:30BWExelixis Announces Appointment of Amy Peterson, M.D., as..
21/08/202302:00BWExelixis and Ipsen Announce Positive Results from Phase 3..
01/08/202317:05BWExelixis Announces Second Quarter 2023 Financial Results and..
23/07/202317:00BWExelixis, Inc. Announces Settlement of CABOMETYX®..
18/07/202317:05BWExelixis to Release Second Quarter 2023 Financial Results on..